日韩欧美精品人妻一区二区_日本免费一区视频_av在线一区二区三区色婷婷_国产精品久久久综合久尹人久久9_日韩女优电影在线观看_午夜福利一区二区在线观看_天天爽夜夜爽人人爽一区二_久久久这里都是精品亚洲女优尤物一区二区_伦交网站_国产诱惑在线视频_a黄色网址网站_天天操夜夜_日韩一区二区黄色大片_日韩欧美一区二区三区四区在线视频_国产丝袜一区二区在线播放

The “Guangdong-Hong Kong-Macao Greater Bay Area Anti-Tumor Drug R&D and Evaluation Center” is co-founded by Lewwin Pharm, the Cancer Research Center of the Hong Kong University of Science and Technology (HKUST), and the laboratory of Professor Chun Liang from the Division of Life Science at HKUST. This initiative integrates the comprehensive advantages of both parties’ key technology platforms in areas including anti-tumor target research, anti-tumor mechanism studies, anti-tumor drug screening, non-clinical pharmacodynamic evaluation of anti-tumor drugs, pharmacokinetic research, safety evaluation, and pharmaceutical research. The collaboration aims to enhance both parties’ capabilities in anti-tumor drug research, development, and innovation; strengthen their innovation capacity and R&D capabilities in the anti-tumor drug field; and advance the comprehensive development of anti-tumor drugs. It also seeks to facilitate the transformation of research outcomes from HKUST's Division of Life Science and Cancer Research Center, turning “innovative ideas” into “innovative products”.

Currently, multiple anti-tumor drugs are undergoing druggability evaluation and screening in the Center. EN002, an original Class 1 innovative drug with a globally novel target developed in collaboration with the Hong Kong University of Science and Technology, has obtained clinical trial implied approval from the CDE and has been established in Guangzhou.